Written question WQ96271
- Asked by
- James EvansConservative
- To be answered by
- Cabinet Secretary for Health and Social Care
- Tabled
- Due
- Answered
- Time to answer
- 8 days
Question
Will the Cabinet Secretary confirm whether the gene-editing therapy Casgevy (exagamglogene autotemcel) is now available to eligible patients with sickle cell disease and transfusion-dependent beta thalassaemia in Wales?
Answer
Answered by Cabinet Secretary for Health and Social Care
In line with recommendations by the National Institute for Health and Care Excellence, Exagamglogene Autotemcel is available for eligible Welsh patients for both transfusion dependent beta-thalassaemia and sickle cell disease, through referral by haematology teams to designated specialised centres.